{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:02Z","timestamp":1792787942807,"version":"4.5.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["FPU18\/02638"],"award-info":[{"award-number":["FPU18\/02638"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["RYC RYC2022-038084-I"],"award-info":[{"award-number":["RYC RYC2022-038084-I"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-115875RBB-I00"],"award-info":[{"award-number":["PID2020-115875RBB-I00"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00573"],"award-info":[{"award-number":["PI23\/00573"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00983"],"award-info":[{"award-number":["PI22\/00983"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI23\/00573"],"award-info":[{"award-number":["PI23\/00573"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00489"],"award-info":[{"award-number":["CB16\/12\/00489"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00443"],"award-info":[{"award-number":["CB16\/12\/00443"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00489"],"award-info":[{"award-number":["CB16\/12\/00489"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00443"],"award-info":[{"award-number":["CB16\/12\/00443"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arnal Planelles Foundation"},{"name":"German Jose Carreras Leukemia research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02352-4","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:13:47Z","timestamp":1748549627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Co-targeting of epigenetic regulators and BCL-XL improves efficacy of immune checkpoint blockade therapy in multiple solid tumors"],"prefix":"10.1186","volume":"24","author":[{"given":"Yaiza","family":"Senent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Fresquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karmele","family":"Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Exposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patxi San","family":"Mart\u00edn-\u00dariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graci\u00e1n","family":"Camps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Fern\u00e1ndez-Pierola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja Ruiz-Fern\u00e1ndez","family":"de C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisol","family":"Gonz\u00e1lez-Huarriz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibon","family":"Tamayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rem\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haritz","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ajona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta M.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lecanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pineda-Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Pr\u00f3sper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel F.","family":"Sanmamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose A.","family":"Martinez-Climent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Pio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2352_CR1","first-page":"55","volume":"61","author":"AJ Weiss","year":"1977","unstructured":"Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, Swaiminathan A, Fletcher WS, Moss SE, Manthei RW. Phase II study of 5 azacytidine in solid tumors. Cancer Treat Rep. 1977;61:55\u20138.","journal-title":"Cancer Treat Rep"},{"key":"2352_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/S00280-002-0563-Y","volume":"51","author":"A Aparicio","year":"2003","unstructured":"Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, Baker SD, Zhao M, Weber JS. Phase I trial of continuous infusion 5-aza-2\u2019-deoxycytidine. Cancer Chemother Pharmacol. 2003;51:231\u20139. https:\/\/doi.org\/10.1007\/S00280-002-0563-Y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2352_CR3","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/JCO.2005.06.118","volume":"23","author":"WE Samlowski","year":"2005","unstructured":"Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol. 2005;23:3897\u2013905. https:\/\/doi.org\/10.1200\/JCO.2005.06.118.","journal-title":"J Clin Oncol"},{"key":"2352_CR4","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-08-2196","volume":"15","author":"DJ Stewart","year":"2009","unstructured":"Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009;15:3881\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2196.","journal-title":"Clin Cancer Res"},{"key":"2352_CR5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/S13148-022-01419-Z","volume":"15","author":"T Feehley","year":"2023","unstructured":"Feehley T, O\u2019Donnell CW, Mendlein J, Karande M, McCauley T. Drugging the epigenome in the age of precision medicine. Clin Epigenetics. 2023;15:6. https:\/\/doi.org\/10.1186\/S13148-022-01419-Z.","journal-title":"Clin Epigenetics"},{"key":"2352_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/S13148-021-01069-7","volume":"13","author":"N Jin","year":"2021","unstructured":"Jin N, George TL, Otterson GA, Verschraegen C, Wen H, Carbone D, Herman J, Bertino EM, He K. Advances in epigenetic therapeutics with focus on solid tumors. Clin Epigenetics. 2021;13:83. https:\/\/doi.org\/10.1186\/S13148-021-01069-7.","journal-title":"Clin Epigenetics"},{"key":"2352_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/NG.3889","volume":"49","author":"D Brocks","year":"2017","unstructured":"Brocks D, Schmidt CR, Daskalakis M, Jang HS, Shah NM, Li D, Li J, Zhang B, Hou Y, Laudato S, Lipka DB, Schott J, Bierhoff H, Assenov Y, Helf M, Ressnerova A, Islam MS, Lindroth AM, Haas S, Essers M, Imbusch CD, Brors B, Oehme I, Witt O, L\u00fcbbert M, Mallm JP, Rippe K, Will R, Weichenhan D, Stoecklin G, Gerh\u00e4user C, Oakes CC, Wang T, Plass C. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat Genet. 2017;49:1052\u201360. https:\/\/doi.org\/10.1038\/NG.3889.","journal-title":"Nat Genet"},{"key":"2352_CR8","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1158\/2159-8290.CD-21-0506","volume":"11","author":"R Chen","year":"2021","unstructured":"Chen R, Ishak CA, De Carvalho DD. Endogenous retroelements and the viral mimicry response in cancer therapy and cellular homeostasis. Cancer Discov. 2021;11:2707\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0506.","journal-title":"Cancer Discov"},{"key":"2352_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/J.CELL.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Mergoub T, Chan TA, Baylin SB, Strick R. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162:974\u201386. https:\/\/doi.org\/10.1016\/J.CELL.2015.07.011.","journal-title":"Cell"},{"key":"2352_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/S41576-019-0106-6","volume":"20","author":"\u00d6 Deniz","year":"2019","unstructured":"Deniz \u00d6, Frost JM, Branco MR. Regulation of transposable elements by DNA modifications. Nat Rev Genet. 2019;20:417\u201331. https:\/\/doi.org\/10.1038\/S41576-019-0106-6.","journal-title":"Nat Rev Genet"},{"key":"2352_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1101\/GR.234229.118","volume":"28","author":"H Ohtani","year":"2018","unstructured":"Ohtani H, Liu M, Zhou W, Liang G, Jones PA. Switching roles for DNA and histone methylation depend on evolutionary ages of human endogenous retroviruses. Genome Res. 2018;28:1147\u201357. https:\/\/doi.org\/10.1101\/GR.234229.118.","journal-title":"Genome Res"},{"key":"2352_CR12","doi-asserted-by":"publisher","unstructured":"D. Roulois, H. Loo Yau, R. Singhania, Y. Wang, A. Danesh, S.Y. Shen, H. Han, G. Liang, P.A. Jones, T.J. Pugh, C. O\u2019Brien, D.D. De Carvalho, DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts, Cell 2015 162;961\u2013973. https:\/\/doi.org\/10.1016\/J.CELL.2015.07.056.","DOI":"10.1016\/J.CELL.2015.07.056"},{"key":"2352_CR13","doi-asserted-by":"publisher","unstructured":"H. Kato, O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A. Jung, T. Kawai, K.J. Ishii, O. Yamaguchi, K. Otsu, T. Tsujimura, C.S. Koh, C. Reis E Sousa, Y. Matsuura, T. Fujita, S. Akira, Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006 441;101\u2013105. https:\/\/doi.org\/10.1038\/NATURE04734.","DOI":"10.1038\/NATURE04734"},{"key":"2352_CR14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/J.CELL.2011.06.041","volume":"146","author":"F Hou","year":"2011","unstructured":"Hou F, Sun L, Zheng H, Skaug B, Jiang QX, Chen ZJ. MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell. 2011;146:448\u201361. https:\/\/doi.org\/10.1016\/J.CELL.2011.06.041.","journal-title":"Cell"},{"key":"2352_CR15","doi-asserted-by":"publisher","unstructured":"M.J. Topper, M. Vaz, K.B. Chiappinelli, C.E. DeStefano Shields, N. Niknafs, R.W.C. Yen, A. Wenzel, J. Hicks, M. Ballew, M. Stone, P.T. Tran, C.A. Zahnow, M.D. Hellmann, V. Anagnostou, P.L. Strissel, R. Strick, V.E. Velculescu, S.B. Baylin, Epigenetic therapy ties MYC depletion to reversing immune evasion and treating lung c\u00e1ncer. Cell 2017 171;1284\u20131300.e21. https:\/\/doi.org\/10.1016\/J.CELL.2017.10.022.","DOI":"10.1016\/J.CELL.2017.10.022"},{"key":"2352_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/J.CELL.2018.05.052","volume":"174","author":"W Sheng","year":"2018","unstructured":"Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, Van Allen EM, Freeman GJ, De Carvalho DD, He HH, Sharpe AH, Shi Y. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell. 2018;174:549-563.e19. https:\/\/doi.org\/10.1016\/J.CELL.2018.05.052.","journal-title":"Cell"},{"key":"2352_CR17","doi-asserted-by":"publisher","first-page":"E10981","DOI":"10.1073\/PNAS.1712514114","volume":"114","author":"ML Stone","year":"2017","unstructured":"Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper MJ, Mathios D, Lim M, Shih IM, Wang TL, Hung CF, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Baylin SB, Zahnow CA. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A. 2017;114:E10981\u201390. https:\/\/doi.org\/10.1073\/PNAS.1712514114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2352_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/CELLS12030365","volume":"12","author":"S Keshari","year":"2023","unstructured":"Keshari S, Barrodia P, Singh AK. Epigenetic perspective of immunotherapy for cancers. Cells. 2023;12:365. https:\/\/doi.org\/10.3390\/CELLS12030365.","journal-title":"Cells"},{"key":"2352_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3322\/CAAC.21765","volume":"73","author":"V Davalos","year":"2023","unstructured":"Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA Cancer J Clin. 2023;73:376\u2013424. https:\/\/doi.org\/10.3322\/CAAC.21765.","journal-title":"CA Cancer J Clin"},{"key":"2352_CR20","doi-asserted-by":"crossref","unstructured":"A.N. Saltos, T. Tanvetyanon, B.C. Creelan, M. Rahman Shafique, S.J. Antonia, E.B. Haura, H. Zheng, X. Yu, J.J. Saller, S. Viracacha, R. Thapa, T.A. Boyle, D.-T. Chen, A.A. Beg, J.E. Gray, Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results, J Clin Oncol 2023 41;9125.","DOI":"10.1200\/JCO.2023.41.16_suppl.9125"},{"key":"2352_CR21","unstructured":"US National Library of Medicine, https:\/\/www.clinicaltrials.gov\/study\/NCT03233724?term=epigenetic%20apoptosis&rank=10&tab=results, (n.d.)."},{"key":"2352_CR22","doi-asserted-by":"publisher","unstructured":"B.P. Levy, G. Giaccone, B. Besse, E. Felip, M.C. Garassino, M. Domine Gomez, P. Garrido, B. Piperdi, S. Ponce-Aix, D. Menezes, K.J. MacBeth, A. Risue\u00f1o, R. Slepetis, X. Wu, A. Fandi, L. Paz-Ares, Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer, Eur J Cancer 2019 108;120\u2013128. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.028.","DOI":"10.1016\/j.ejca.2018.11.028"},{"key":"2352_CR23","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/2159-8290.cd-20-1065","volume":"11","author":"V Fresquet","year":"2021","unstructured":"Fresquet V, Garcia-Barchino MJ, Larrayoz MJ, Celay J, Vicente C, Fernandez-Galilea M, Larrayoz MJ, Calasanz MJ, Panizo C, Junza A, Han J, Prior C, Fortes P, Pio R, Oyarzabal J, Mart\u00ednez-Bazt\u00e1n \u00c1, Paiva B, Moreno-Aliaga MJ, Odero MD, Agirre X, Yanes O, Pr\u00f3sper F, Martinez-Climent JA. Endogenous retroelement activation by epigenetic therapy reverses the Warburg effect and elicits mitochondrial-mediated cancer cell death. Cancer Discov. 2021;11:1268\u201385. https:\/\/doi.org\/10.1158\/2159-8290.cd-20-1065.","journal-title":"Cancer Discov"},{"key":"2352_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/S41580-018-0089-8","volume":"20","author":"R Singh","year":"2019","unstructured":"Singh R, Letai A, Sarosiek K. Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol. 2019;20:175\u201393. https:\/\/doi.org\/10.1038\/S41580-018-0089-8.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2352_CR25","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMOA2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, H\u00e1jek R, Porkka K, Ill\u00e9s \u00c1, Lavie D, Lemoli RM, Yamamoto K, Yoon S-S, Jang J-H, Yeh S-P, Turgut M, Hong W-J, Zhou Y, Potluri J, Pratz KW. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMOA2012971.","journal-title":"N Engl J Med"},{"key":"2352_CR26","doi-asserted-by":"publisher","unstructured":"E. San Jos\u00e9-En\u00e9riz, X. Agirre, O. Rabal, A. Vilas-Zornoza, J.A. Sanchez-Arias, E. Miranda, A. Ugarte, S. Roa, B. Paiva, A. Estella-Hermoso De Mendoza, R.M. Mar\u00eda Alvarez, N. Casares, V. Segura, J.I. Mart\u00edn-Subero, F.X. Ogi, P. Soule, C.M. Santiveri, R. Campos-Olivas, G. Castellano, M. Garcia Fernandez De Barrena, J.R. Rodriguez-Madoz, M.J. Garc\u00eda-Barchino, J.J. Lasarte, M.A. Avila, J.A. Martinez-Climent, J. Oyarzabal, F. Prosper, Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies, Nat Commun 2017 8;15424. https:\/\/doi.org\/10.1038\/NCOMMS15424.","DOI":"10.1038\/NCOMMS15424"},{"key":"2352_CR27","doi-asserted-by":"publisher","unstructured":"K. Valencia, C. Sainz, C. B\u00e9rtolo, G. de Biurrun, J. Agorreta, A. Azpilikueta, M.J. Larrayoz, G. Bosco, C. Zandueta, M. Redrado, E. Red\u00edn, F. Exposito, D. Serrano, M. Echepare, D. Ajona, I. Melero, R. Pio, R. Thomas, A. Calvo, L.M. Montuenga, Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma, Dis Model Mech 2022 15;dmm049137. https:\/\/doi.org\/10.1242\/DMM.049137.","DOI":"10.1242\/DMM.049137"},{"key":"2352_CR28","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1158\/2159-8290.CD-21-0932","volume":"12","author":"B Ruiz-Fern\u00e1ndez de C\u00f3rdoba","year":"2022","unstructured":"Ruiz-Fern\u00e1ndez de C\u00f3rdoba B, Moreno H, Valencia K, Perurena N, Ruedas P, Walle T, Pezonaga-Torres A, Hinojosa J, Guruceaga E, Pineda-Lucena A, Abeng\u00f3zar-Muela M, Cochonneau D, Zandueta C, Mart\u00ednez-Canarias S, Teijeira \u00c1, Ajona D, Ortiz-Espinosa S, Morales X, Ortiz de Sol\u00f3rzano C, Santisteban M, Ramos-Garc\u00eda LI, Guembe L, Strnad V, Heymann D, Herv\u00e1s-Stubbs S, P\u00edo R, Rodr\u00edguez-Ruiz ME, de Andrea CE, Vicent S, Melero I, Lecanda F, Mart\u00ednez-Monge R. Tumor ENPP1 (CD203a)\/haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancer. Cancer Discov. 2022;12:1356\u201377. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0932.","journal-title":"Cancer Discov"},{"key":"2352_CR29","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/NEUONC\/NOY007","volume":"20","author":"G Aldave","year":"2018","unstructured":"Aldave G, Gonzalez-Huarriz M, Rubio A, Romero JP, Ravi D, Mi\u00f1ana B, Cuadrado-Tejedor M, Garc\u00eda-Osta A, Verhaak R, Xipell E, Martinez-V\u00e9lez N, De La Rocha AA, Puigdelloses M, Garc\u00eda-Moure M, Marigil M, P\u00e9rez-Larraya JG, Mar\u00edn-Bejar O, Huarte M, Carro MS, Ferrarese R, Belda-Iniesta C, Ayuso A, Prat-Ac\u00edn R, Pastor F, D\u00edez-Valle R, Tejada S, Alonso MM. The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma. Neuro Oncol. 2018;20:930\u201341. https:\/\/doi.org\/10.1093\/NEUONC\/NOY007.","journal-title":"Neuro Oncol"},{"key":"2352_CR30","doi-asserted-by":"publisher","unstructured":"I. Eguren-Santamaria, E. Fern\u00e1ndez de Pi\u00e9rola, G. Camps, P. Mart\u00edn-Mu\u00f1oz, M. Campos, D. Cuculescu, I. Aguilera-Buenosvinos, I. Rodr\u00edguez L\u00f3pez, R. Salido-Vallejo, R. Alexandru, C.E. De Andrea, L. \u00c1lvarez-Gigli, P. Berraondo, I. Melero, M.F. Sanmamed, MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers, J Immunother Cancer 2024 12;e008516. https:\/\/doi.org\/10.1136\/JITC-2023-008516.","DOI":"10.1136\/JITC-2023-008516"},{"key":"2352_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/S43018-019-0007-9","volume":"1","author":"D Ajona","year":"2020","unstructured":"Ajona D, Ortiz-Espinosa S, Lozano T, Exposito F, Calvo A, Valencia K, Redrado M, Rem\u00edrez A, Lecanda F, Alignani D, Lasarte JJ, Macaya I, Senent Y, B\u00e9rtolo C, Sainz C, Gil-Bazo I, Eguren-Santamar\u00eda I, Lopez-Picazo JM, Gonzalez A, Perez-Gracia JL, de Andrea CE, Vicent S, Sanmamed MF, Montuenga LM, Pio R. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade. Nat Cancer. 2020;1:75\u201385. https:\/\/doi.org\/10.1038\/S43018-019-0007-9.","journal-title":"Nat Cancer"},{"key":"2352_CR32","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","volume":"7","author":"D Ajona","year":"2017","unstructured":"Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, B\u00e9rtolo C, Lasarte JJ, Vicent S, Hoehlig K, Vater A, Lecanda F, Montuenga LM, Pio R. A combined PD-1\/C5a blockade synergistically protects against lung cancer growth and metastasis. Cancer Discov. 2017;7:694\u2013703. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1184.","journal-title":"Cancer Discov"},{"key":"2352_CR33","doi-asserted-by":"publisher","unstructured":"Villalba, Exposito, Pajares, Sainz, Redrado, Remirez, Wistuba, Behrens, Jantus-Lewintre, Camps, Montuenga, Pio, Lozano, de Andrea, Calvo, TMPRSS4: A novel tumor prognostic indicator for the stratification of stage IA tumors and a liquid biopsy biomarker for NSCLC patients, J Clin Med 2019 8;2134. https:\/\/doi.org\/10.3390\/jcm8122134","DOI":"10.3390\/jcm8122134"},{"key":"2352_CR34","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/S41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, McQuaid S, Gray RT, Murray LJ, Coleman HG, James JA, Salto-Tellez M, Hamilton PW. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878. https:\/\/doi.org\/10.1038\/S41598-017-17204-5.","journal-title":"Sci Rep"},{"key":"2352_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/S13059-019-1662-Y","volume":"20","author":"ATL Lun","year":"2019","unstructured":"Lun ATL, Riesenfeld S, Andrews T, Dao TP, Gomes T, Marioni JC. EmptyDrops: Distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data. Genome Biol. 2019;20:63. https:\/\/doi.org\/10.1186\/S13059-019-1662-Y.","journal-title":"Genome Biol"},{"key":"2352_CR36","doi-asserted-by":"publisher","unstructured":"P.L. Germain, M.D. Robinson, A. Lun, C. Garcia Meixide, W. Macnair, Doublet identification in single-cell sequencing data using scDblFinder, F1000Res 2022 10 979. https:\/\/doi.org\/10.12688\/F1000RESEARCH.73600.2\/DOI.","DOI":"10.12688\/F1000RESEARCH.73600.2\/DOI"},{"key":"2352_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/NBT.4091","volume":"36","author":"L Haghverdi","year":"2018","unstructured":"Haghverdi L, Lun ATL, Morgan MD, Marioni JC. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol. 2018;36:421\u20137. https:\/\/doi.org\/10.1038\/NBT.4091.","journal-title":"Nat Biotechnol"},{"key":"2352_CR38","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/BIOINFORMATICS\/BTW777","volume":"33","author":"DJ McCarthy","year":"2017","unstructured":"McCarthy DJ, Campbell KR, Lun ATL, Wills QF. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics. 2017;33:1179\u201386. https:\/\/doi.org\/10.1093\/BIOINFORMATICS\/BTW777.","journal-title":"Bioinformatics"},{"key":"2352_CR39","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1038\/S41598-019-41695-Z","volume":"9","author":"VA Traag","year":"2019","unstructured":"Traag VA, Waltman L, van Eck NJ. From Louvain to Leiden: Guaranteeing well-connected communities. Sci Rep. 2019;9:5233. https:\/\/doi.org\/10.1038\/S41598-019-41695-Z.","journal-title":"Sci Rep"},{"key":"2352_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/S41586-018-0694-X","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q, Gao R, Kang B, Zhang Q, Huang JY, Konno H, Guo X, Ye Y, Gao S, Wang S, Hu X, Ren X, Shen Z, Ouyang W, Zhang Z. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature. 2018;564:268\u201372. https:\/\/doi.org\/10.1038\/S41586-018-0694-X.","journal-title":"Nature"},{"key":"2352_CR41","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/J.MOLCEL.2015.03.014","volume":"58","author":"H Yao","year":"2015","unstructured":"Yao H, Dittmann M, Peisley A, Hoffmann HH, Gilmore RH, Schmidt T, Schmid-Burgk JL, Hornung V, Rice CM, Hur S. ATP-dependent effector-like functions of RIG-I-like receptors. Mol Cell. 2015;58:541\u20138. https:\/\/doi.org\/10.1016\/J.MOLCEL.2015.03.014.","journal-title":"Mol Cell"},{"key":"2352_CR42","doi-asserted-by":"publisher","first-page":"21010","DOI":"10.1073\/PNAS.1113651108\/-\/DCSUPPLEMENTAL\/PNAS.1113651108_SI.PDF","volume":"108","author":"A Peisley","year":"2011","unstructured":"Peisley A, Lin C, Wu B, Orme-Johnson M, Liu M, Walz T, Hur S. Cooperative assembly and dynamic disassembly of MDA5 filaments for viral dsRNA recognition. Proc Natl Acad Sci U S A. 2011;108:21010\u20135. https:\/\/doi.org\/10.1073\/PNAS.1113651108\/-\/DCSUPPLEMENTAL\/PNAS.1113651108_SI.PDF.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2352_CR43","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/J.CCELL.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41:450\u201365. https:\/\/doi.org\/10.1016\/J.CCELL.2023.02.014.","journal-title":"Cancer Cell"},{"key":"2352_CR44","doi-asserted-by":"publisher","unstructured":"A.S. Syed Khaja, S.M. Toor, H.E. Salhat, B.R. Ali, E. Elkord, Intratumoral FoxP3+Helios+ regulatory T cells upregulating immunosuppressive molecules Are expanded in human colorectal cancer, Front Immunol 2017 8;619. https:\/\/doi.org\/10.3389\/FIMMU.2017.00619.","DOI":"10.3389\/FIMMU.2017.00619"},{"key":"2352_CR45","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.1038\/S41467-021-26352-2","volume":"12","author":"A Lain\u00e9","year":"2021","unstructured":"Lain\u00e9 A, Labiad O, Hernandez-Vargas H, This S, Sanlaville A, L\u00e9on S, Dalle S, Sheppard D, Travis MA, Paidassi H, Marie JC. Regulatory T cells promote cancer immune-escape through integrin \u03b1v\u03b28-mediated TGF-\u03b2 activation. Nat Commun. 2021;12:6228. https:\/\/doi.org\/10.1038\/S41467-021-26352-2.","journal-title":"Nat Commun"},{"key":"2352_CR46","doi-asserted-by":"publisher","first-page":"984550","DOI":"10.4161\/2162402X.2014.984550","volume":"4","author":"MS Ahmed","year":"2015","unstructured":"Ahmed MS, Byeon SE, Jeong Y, Miah MA, Salahuddin M, Lee Y, Park SS, Bae YS. Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy. Oncoimmunology. 2015;4:984550. https:\/\/doi.org\/10.4161\/2162402X.2014.984550.","journal-title":"Oncoimmunology"},{"key":"2352_CR47","doi-asserted-by":"publisher","unstructured":"F. Exposito, M. Redrado, D. Serrano, S. Calabuig-Fari\u00f1as, A. Bao-Caamano, S. Gallach, E. Jantus-Lewintre, A. Diaz-Lagares, A. Rodriguez-Casanova, J. Sandoval, E. San Jose-Eneriz, J. Garcia, E. Redin, Y. Senent, S. Leon, R. Pio, R. Lopez, J. Oyarzabal, A. Pineda-Lucena, X. Agirre, L.M. Montuenga, F. Prosper, A. Calvo, G9a\/DNMT1 co-targeting inhibits non-small cell lung cancer growth and reprograms tumor cells to respond to cancer-drugs through SCARA5 and AOX1, Cell Death Dis 2024 15;787. https:\/\/doi.org\/10.1038\/S41419-024-07156-W.","DOI":"10.1038\/S41419-024-07156-W"},{"key":"2352_CR48","doi-asserted-by":"publisher","unstructured":"M. B\u00e1rcena-Varela, S. Caruso, S. Llerena, G. \u00c1lvarez-Sola, I. Uriarte, M.U. Latasa, R. Urtasun, S. Rebouissou, L. Alvarez, M. Jimenez, E. Santamar\u00eda, C. Rodriguez-Ortigosa, G. Mazza, K. Rombouts, E. San Jos\u00e9-Eneriz, O. Rabal, X. Agirre, M. Iraburu, A. Santos-Laso, J.M. Banales, J. Zucman-Rossi, F. Pr\u00f3sper, J. Oyarzabal, C. Berasain, M.A. \u00c1vila, M.G. Fern\u00e1ndez-Barrena, Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma, Hepatology 2019 69;587\u2013603. https:\/\/doi.org\/10.1002\/HEP.30168.","DOI":"10.1002\/HEP.30168"},{"key":"2352_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/S13046-024-03268-5","volume":"44","author":"D Oyon","year":"2025","unstructured":"Oyon D, Lopez-Pascual A, Castello-Uribe B, Uriarte I, Orsi G, Llorente S, Elurbide J, Adan-Villaescusa E, Valbuena-Goiricelaya E, Irigaray-Miramon A, Latasa MU, Martinez-Perez LA, Bonetti LR, Prosper F, Ponz-Sarvise M, Vicent S, Pineda-Lucena A, Ruiz-Clavijo D, Sangro B, Larracoechea UA, Tian TV, Casadei-Gardini A, Amat I, Arechederra M, Berasain C, Urman JM, Avila MA, Fernandez-Barrena MG. Targeting of the G9a, DNMT1 and UHRF1 epigenetic complex as an effective strategy against pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res. 2025;44:13. https:\/\/doi.org\/10.1186\/S13046-024-03268-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"2352_CR50","doi-asserted-by":"publisher","unstructured":"C. Segovia, E. San Jos\u00e9-En\u00e9riz, E. Munera-Maravilla, M. Mart\u00ednez-Fern\u00e1ndez, L. Garate, E. Miranda, A. Vilas-Zornoza, I. Lodewijk, C. Rubio, C. Segrelles, L.V. Valc\u00e1rcel, O. Rabal, N. Casares, A. Bernardini, C. Suarez-Cabrera, F.F. L\u00f3pez-Calder\u00f3n, P. Fortes, J.A. Casado, M. Due\u00f1as, F. Villacampa, J.J. Lasarte, F. Guerrero-Ramos, G. de Velasco, J. Oyarzabal, D. Castellano, X. Agirre, F. Pr\u00f3sper, J.M. Paramio, Inhibition of a G9a\/DNMT network triggers immune-mediated bladder cancer regression, Nat Med 2019 25;1073\u20131081. https:\/\/doi.org\/10.1038\/S41591-019-0499-Y.","DOI":"10.1038\/S41591-019-0499-Y"},{"key":"2352_CR51","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ygyno.2004.10.026","volume":"96","author":"J Williams","year":"2005","unstructured":"Williams J, Lucas PC, Griffith KA, Choi M, Fogoros S, Hu YY, Liu JR. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol. 2005;96:287\u201395. https:\/\/doi.org\/10.1016\/j.ygyno.2004.10.026.","journal-title":"Gynecol Oncol"},{"key":"2352_CR52","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41419-020-03092-7","volume":"11","author":"A-L Scherr","year":"2020","unstructured":"Scherr A-L, Mock A, Gdynia G, Schmitt N, Heilig CE, Korell F, Rhadakrishnan P, Hoffmeister P, Metzeler KH, Schulze-Osthoff K, Illert AL, Boerries M, Trojan J, Waidmann O, Falkenhorst J, Siveke J, Jost PJ, Bitzer M, Malek NP, Vecchione L, Jelas I, Brors B, Glimm H, Stenzinger A, Grekova SP, Gehrig T, Schulze-Bergkamen H, J\u00e4ger D, Schirmacher P, Heikenwalder M, Goeppert B, Schneider M, Fr\u00f6hling S, K\u00f6hler BC. Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer. Cell Death Dis. 2020;11:875. https:\/\/doi.org\/10.1038\/s41419-020-03092-7.","journal-title":"Cell Death Dis"},{"key":"2352_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.canlet.2017.09.025","volume":"412","author":"SF Faqar-Uz-Zaman","year":"2018","unstructured":"Faqar-Uz-Zaman SF, Heinicke U, Meister MT, Vogler M, Fulda S. BCL-xL-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. Cancer Lett. 2018;412:131\u201342. https:\/\/doi.org\/10.1016\/j.canlet.2017.09.025.","journal-title":"Cancer Lett"},{"key":"2352_CR54","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1158\/1078-0432.CCR-10-2353","volume":"17","author":"N Tan","year":"2011","unstructured":"Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, Fairbrother WJ, Sampath D, Belmont LD. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res. 2011;17:1394\u2013404. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2353.","journal-title":"Clin Cancer Res"},{"key":"2352_CR55","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0928","volume":"14","author":"Y Xiao","year":"2015","unstructured":"Xiao Y, Nimmer P, Sheppard GS, Bruncko M, Hessler P, Lu X, Roberts-Rapp L, Pappano WN, Elmore SW, Souers AJ, Leverson JD, Phillips DC. MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther. 2015;14:1837\u201347. https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0928.","journal-title":"Mol Cancer Ther"},{"key":"2352_CR56","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1038\/onc.2010.559","volume":"30","author":"H Zhang","year":"2011","unstructured":"Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW, Leverson JD, Lam LT. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene. 2011;30:1963\u20138. https:\/\/doi.org\/10.1038\/onc.2010.559.","journal-title":"Oncogene"},{"key":"2352_CR57","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.4161\/cbt.5.10.3224","volume":"5","author":"V Wacheck","year":"2006","unstructured":"Wacheck V, Cejka D, Sieghart W, Losert D, Strommer S, Crevenna R, Monia BP, Selzer E. Mcl-1 is a relevant molecular target for antisense oligonucleotide strategies in gastric cancer cells. Cancer Biol Ther. 2006;5:1348\u201354. https:\/\/doi.org\/10.4161\/cbt.5.10.3224.","journal-title":"Cancer Biol Ther"},{"key":"2352_CR58","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.02.028","volume":"21","author":"G Wei","year":"2012","unstructured":"Wei G, Margolin AA, Haery L, Brown E, Cucolo L, Julian B, Shehata S, Kung AL, Beroukhim R, Golub TR. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21:547\u201362. https:\/\/doi.org\/10.1016\/j.ccr.2012.02.028.","journal-title":"Cancer Cell"},{"key":"2352_CR59","doi-asserted-by":"publisher","first-page":"4527","DOI":"10.1038\/s41467-020-18372-1","volume":"11","author":"E Munkhbaatar","year":"2020","unstructured":"Munkhbaatar E, Dietzen M, Agrawal D, Anton M, Jesinghaus M, Boxberg M, Pfarr N, Bidola P, Uhrig S, H\u00f6ckendorf U, Meinhardt A-L, Wahida A, Heid I, Braren R, Mishra R, Warth A, Muley T, Poh PSP, Wang X, Fr\u00f6hling S, Steiger K, Slotta-Huspenina J, van Griensven M, Pfeiffer F, Lange S, Rad R, Spella M, Stathopoulos GT, Ruland J, Bassermann F, Weichert W, Strasser A, Branca C, Heikenwalder M, Swanton C, McGranahan N, Jost PJ. MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically. Nat Commun. 2020;11:4527. https:\/\/doi.org\/10.1038\/s41467-020-18372-1.","journal-title":"Nat Commun"},{"key":"2352_CR60","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/15384047.2020.1856756","volume":"22","author":"MJ Kim","year":"2021","unstructured":"Kim MJ, Chen G, Sica GL, Deng X. Epigenetic modulation of FBW7\/Mcl-1 pathway for lung cancer therapy. Cancer Biol Ther. 2021;22:55\u201365. https:\/\/doi.org\/10.1080\/15384047.2020.1856756.","journal-title":"Cancer Biol Ther"},{"key":"2352_CR61","doi-asserted-by":"publisher","unstructured":"K.J. Campbell, S.W.G. Tait, Targeting BCL-2 regulated apoptosis in cancer, Open Biol 2018 8. https:\/\/doi.org\/10.1098\/rsob.180002.","DOI":"10.1098\/rsob.180002"},{"key":"2352_CR62","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/ncomms16078","volume":"8","author":"A Inoue-Yamauchi","year":"2017","unstructured":"Inoue-Yamauchi A, Jeng PS, Kim K, Chen H-C, Han S, Ganesan YT, Ishizawa K, Jebiwott S, Dong Y, Pietanza MC, Hellmann MD, Kris MG, Hsieh JJ, Cheng EH. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun. 2017;8:16078. https:\/\/doi.org\/10.1038\/ncomms16078.","journal-title":"Nat Commun"},{"key":"2352_CR63","doi-asserted-by":"publisher","first-page":"19103","DOI":"10.1074\/JBC.M112.434530","volume":"288","author":"X Hu","year":"2013","unstructured":"Hu X, Bardhan K, Paschall AV, Yang D, Waller JL, Park MA, Nayak-Kapoor A, Samuel TA, Abrams SI, Liu K. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. J Biol Chem. 2013;288:19103\u201315. https:\/\/doi.org\/10.1074\/JBC.M112.434530.","journal-title":"J Biol Chem"},{"key":"2352_CR64","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/BLOODADVANCES.2020004139","volume":"5","author":"EM Carrington","year":"2021","unstructured":"Carrington EM, Louis C, Kratina T, Hancock M, Keenan CR, Iannarella N, Allan RS, Wardak AZ, Czabotar PE, Herold MJ, Schenk RL, White CA, D\u2019Silva D, Yang Y, Wong W, Wong H, Bryant VL, Huntington ND, Rautela J, Sutherland RM, Zhan Y, Hansen J, Nhu D, Lessene G, Wicks IP, Lew AM. BCL-XL antagonism selectively reduces neutrophil life span within inflamed tissues without causing neutropenia. Blood Adv. 2021;5:2550\u201362. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020004139.","journal-title":"Blood Adv"},{"key":"2352_CR65","doi-asserted-by":"publisher","first-page":"4044","DOI":"10.1073\/PNAS.1417620112","volume":"112","author":"EM Carrington","year":"2015","unstructured":"Carrington EM, Zhang JG, Sutherland RM, Vikstrom IB, Brady JL, Soo P, Vremec D, Allison C, Lee EF, Fairlie WD, Bouillet P, Grabow S, Ottina E, Herold MJ, Pellegrini M, Huang DCS, Tarlinton DM, Strasser A, Lew AM, Zhan Y. Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells. Proc Natl Acad Sci U S A. 2015;112:4044\u20139. https:\/\/doi.org\/10.1073\/PNAS.1417620112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2352_CR66","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/2159-8290.CD-22-1338","volume":"13","author":"L Zhao","year":"2023","unstructured":"Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre CA, Lehmann CHK, Pan H, Paulhan N, Amon L, Buqu\u00e9 A, Yamazaki T, Galluzzi L, Kloeckner B, Silvin A, Pan Y, Chen H, Tian AL, Ly P, Dudziak D, Zitvogel L, Kepp O, Kroemer G. BCL2 inhibition reveals a dendritic cell-specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 2023;13:2448\u201369. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1338.","journal-title":"Cancer Discov"},{"key":"2352_CR67","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1038\/S41467-021-21573-X","volume":"12","author":"R Kolb","year":"2021","unstructured":"Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021;12:1281. https:\/\/doi.org\/10.1038\/S41467-021-21573-X.","journal-title":"Nat Commun"},{"key":"2352_CR68","doi-asserted-by":"publisher","unstructured":"A.S. Syed Khaja, S.M. Toor, H. El Salhat, I. Faour, N. ul Haq, B.R. Ali, E. Elkord, Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment, Oncotarget 2017 8;33159\u201333171. https:\/\/doi.org\/10.18632\/ONCOTARGET.16565.","DOI":"10.18632\/ONCOTARGET.16565"},{"key":"2352_CR69","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/IMCB.12492","volume":"99","author":"C Lu","year":"2021","unstructured":"Lu C, Chen W. Influenza virus infection selectively triggers the accumulation and persistence of more potent Helios-expressing Foxp3+ regulatory T cells in the lungs. Immunol Cell Biol. 2021;99:1011\u201325. https:\/\/doi.org\/10.1111\/IMCB.12492.","journal-title":"Immunol Cell Biol"},{"key":"2352_CR70","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/S41419-020-03144-Y","volume":"11","author":"I Kapoor","year":"2020","unstructured":"Kapoor I, Bodo J, Hill BT, Hsi ED, Almasan A. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance. Cell Death Dis. 2020;11:941. https:\/\/doi.org\/10.1038\/S41419-020-03144-Y.","journal-title":"Cell Death Dis"},{"key":"2352_CR71","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","volume":"18","author":"CM Rudin","year":"2012","unstructured":"Rudin CM, Hann CL, Garon EB, Ribeiro De Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3090.","journal-title":"Clin Cancer Res"},{"key":"2352_CR72","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1182\/BLOOD-2011-04-347849","volume":"118","author":"SM Schoenwaelder","year":"2011","unstructured":"Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, Josefsson EC, Alwis I, Ono A, Willcox A, Andrews RK, Mason KD, Salem HH, Huang DCS, Kile BT, Roberts AW, Jackson SP. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. 2011;118:1663\u201374. https:\/\/doi.org\/10.1182\/BLOOD-2011-04-347849.","journal-title":"Blood"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02352-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02352-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02352-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T20:13:50Z","timestamp":1748549630000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02352-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2352"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02352-4","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAM-C received funding for research from Roche-Genentech, Bristol Myers Squibb-Celgene, Janssen, Regeneron, Priothera Pharmaceuticals, Palleon Pharmaceuticals, AstraZeneca, and K36 Therapeutics; is inventor on a patent \u2018Genetically engineered animal models for multiple myeloma\u2019 licensed to MIMO Biosciences; and is founder, holder of stock options, and royalties in MIMO Biosciences, all unrelated to this study. The other authors declare no conflict of interest.The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}